Company News
Theriva Biologics Stock Surges 73.6% on AACR Data
Theriva Biologics shares jumped 73.6% on April 21, 2026 after releasing Phase 2b VIRAGE trial data at AACR meeting.
VCN-01 combined with gemcitabine/nab-paclitaxel showed improved overall survival and
